Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Deutivacaftor · Alyftrek, VX-561

Small molecule · Modulator of CFTR · developed by Vertex Pharmaceuticals

Approved FDA

VRTX Developer

2 Registered trials

What is Deutivacaftor?

Deutivacaftor is a CFTR potentiator that increases channel open probability of the CFTR protein at the cell surface. In combination with vanzacaftor and tezacaftor (ALYFTREK), it enhances CFTR quantity and function to increase chloride transport, treating cystic fibrosis in patients 6 years and older with responsive CFTR variants.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Alyftrek, VX-561, CTP-656, D-IVA
Drug type: Small molecule
Targets: CFTR
Mechanism: Modulator of CFTR
Pathways: chloride transport, CFTR gating
Therapy area: Respiratory
Developer: Vertex Pharmaceuticals Incorporated (VRTX)
FDA status: Approved as Alyftrek, NDA218730 · FDA label
UNII: SHA6U5FJZL

✅ FDA-approved uses

Cystic fibrosis

From the indications section of the FDA label (version of Aug 26, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07437105	Phase 1	Cystic Fibrosis	Recruiting	VRTX
NCT07283770	Phase 1	Cystic Fibrosis	Recruiting	VRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cystic Fibrosis

Other drugs acting on CFTR

Elexacaftor FDA approved Ivacaftor FDA approved Tezacaftor FDA approved Vanzacaftor FDA approved

More from Vertex Pharmaceuticals

Elexacaftor FDA approved Exagamglogene Autotemcel FDA approved Ivacaftor FDA approved Suzetrigine FDA approved Tezacaftor FDA approved Vanzacaftor FDA approved Inaxaplin Phase 2/3 Povetacicept Phase 2/3 VX-017 Phase 3 VX-118 Phase 1 VX-264 Phase 1/2 VX-272 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the VRTX page.

Follow VRTX, the company behind Deutivacaftor

See VRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VRTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z